Ponazuril

Ponazuril

Clinical data
Trade names	Marquis
AHFS/Drugs.com	FDA Professional Drug Information
Routes of administration	Oral
ATCvet code	QP51AJ04 (WHO)
Legal status
Legal status	US: ℞-only Veterinary use only
Identifiers
IUPAC name 1-Methyl-3-[3-methyl-4-[4-(trifluoromethylsulfonyl)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione
CAS Number	69004-04-2
PubChem (CID)	3050408
ChemSpider	2312474
UNII	JPW84AS66U
ECHA InfoCard	100.157.907
Chemical and physical data
Formula	C18H14F3N3O6S
Molar mass	457.380 g/mol
3D model (Jmol)	Interactive image
SMILES CC1=C(C=CC(=C1)N2C(=O)NC(=O)N(C2=O)C)OC3=CC=C(C=C3)S(=O)(=O)C(F)(F)F
InChI InChI=1S/C18H14F3N3O6S/c1-10-9-11(24-16(26)22-15(25)23(2)17(24)27)3-8-14(10)30-12-4-6-13(7-5-12)31(28,29)18(19,20)21/h3-9H,1-2H3,(H,22,25,26) Key:VBUNOIXRZNJNAD-UHFFFAOYSA-N
(verify)

Ponazuril (INN), sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by Sarcocystis neurona.^[1][2] More recently, veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia, an intestinal parasite. Coccidia treatment is far shorter than treatment for EPM.

See also

• Clazuril
• Diclazuril
• Toltrazuril

References

1. Marquis FDA Professional Drug Information
2. MacKay, R. J.; Tanhauser, S. T.; Gillis, K. D.; Mayhew, I. G.; Kennedy, T. J. (2008). "Effect of intermittent oral administration of ponazuril on experimentalSarcocystis neuronainfection of horses". American Journal of Veterinary Research. 69 (3): 396–402. doi:10.2460/ajvr.69.3.396. PMID 18312139.